Amgen launched multiple late-stage obesity trials for MariTide, including a study designed to evaluate the drug in patients switching away from rival GLP-1 therapies from Eli Lilly and Novo Nordisk. The program structure is aimed at capturing real-world treatment sequences where patients discontinue due to tolerability, efficacy, or access. The design reflects growing competition in obesity medicine, where differentiation increasingly depends on positioning within treatment lines rather than first-line efficacy alone. The switching trial is expected to help clarify whether MariTide performs for patients who have already cycled through established GLP-1 options. Amgen’s step also signals that obesity pipelines are shifting toward operationally meaningful endpoints for payer and clinician decision-making.